01992nas a2200229   4500008004100000024000700041245004900048210004700097260001600144300001200160490000700172520137000179653001101549653001901560653001601579653002201595653002801617653002601645100002801671700002301699856004001722       2024                        eng d  a3900aIrritant-Induced Asthma: A Literature Review0 aIrritantInduced Asthma A Literature Review  cAugust 2024  a982-9880 v163 a<p class="rtejustify">One of occupational illnesses is irritant-induced asthma (IIA), which IIA is a phenotype of asthma caused by the inhalation of irritant agents. The incidence of IIA is reported as 5-18% of occupational asthma cases. In some cases, it is challenging to differentiate IIA from work-exacerbated asthma (WEA) because no specific diagnostic tests can determine whether a person has asthma caused by exposure to irritants. In any case of suspected IIA, the diagnosis of asthma should be confirmed by spirometry demonstrating airflow limitation with significant bronchodilator response or nonspecific bronchial hyperresponsiveness (NSBHR) to methacholine/histamine. IIA Management is similar to asthma management, including bronchodilator therapy and inhaled and/or systemic corticosteroids. Several studies recommend treating asthma in adults and adolescents with short-acting beta-agonists (SABA), adding a controller in the form of inhaled corticosteroids (ICS) as needed to reduce the risk of severe exacerbations and to control symptoms. This type of controller can be given regularly every day, or ICS-formoterol can be given as needed to relieve symptoms in mild asthma. Prevention that can be done at IIA includes health promotion, special protection, early diagnosis and early treatment, limitation of disabilities, and rehabilitation.</p>
10aAsthma10aBronchodilator10aHealth risk10aIrritant exposure10aIrritant-induced asthma10aOccupational illness.1 aVendarani, Yoni, Frista1 aEffendi, Wiwin, Is  uhttps://www.phcogj.com/article/2368